Cullinan Therapeutics, Inc. CGEM
NASDAQ · United States · Health Technology
$14.98-0.37 (-2.41%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.